Positron emission tomography (PET)  scanning is an imaging modality with primary use in the field of oncology. It utilizes radiotracers for measuring various metabolic processes in the body. Various changes in metabolism, blood flow, and regional chemical composition can be analyzed by it. Radio-tracers can be injected, swallowed, or inhaled depending upon the site of the body being examined, and the tracer gets trapped in various tissues of the body depending upon the affinity. Areas of higher activity show higher uptake and brighter spots on images. Unstable nuclei of radioactive-tracer emit positrons that produce gamma rays upon the combination with the neighboring electrons. The gamma rays are detected by a ring of detectors in the scanner. A computer then uses this data to create a 3D-image of the tracer in the body. Various tracers are utilized depending on the targets.

The tracer may be administered via an intravenous route, orally or via inhalation. The tracer takes some time to distribute throughout the body. A contrast may be administered intravenously or orally if a PET-CT is to be done. Positioning depends upon the site to be scanned. The PET machine has a central hole through which the patient slides through. First images are generally scout images to assess whether the positioning is correct. Sometimes breath-holding maybe required. The scan takes anything from 30 minutes to 1 hour.

Oncology

Tracers used commonly include fluorine-18 (18F) fluoro-deoxyglucose (FDG), called [18F] FDG PET. 18F-FDG being a glucose analog, gets picked up by the cells instead of regular glucose for metabolism. Glucose gets phosphorylated by hexokinases. The values of the mitochondrial form of this enzyme are raised in cancers that are rapidly growing. In locations of cancer, the metabolic activity is quite high; hence the glucose uptake is quite high. So this 18F-FDG also gets taken up quite significantly in these locations, and then this shows up as a bright spot on the PET scan. This helps in the detection of metastasis also. Typical doses amount to 7.5 mSv.[1] In the generation of 18-F FDG, the hydroxyl group is replaced by radioactive Fluorine. This hydroxyl group is essential in glucose metabolism steps & its absence causes the stoppage of further reactions in the cells. Most tissues (except liver & kidney) can’t remove the phosphate which hexokinase has added. So, the 18F-FDG gets trapped inside the cell till its decay. This is because phosphorylation of sugar leads to the development of ionic charge, which prevents the exit of the sugar from the cell till its decay. Hence tissues with higher glucose uptake & utilization like brain, liver, kidneys, and most of the cancers (due to Warburg effect) show intensive radio-labeling.

FDG-PET is used for diagnosis, staging, and monitoring cancers, particularly in Hodgkin's lymphoma,[2] non-Hodgkin lymphoma,[3], and lung cancer.[4][5][6] In a study, the likelihood ratio for malignancy in a solitary pulmonary nodule with an abnormal FDG-PET scan was 7.11. This study suggested that the FDG-PET scan is more accurate than the standard criteria for diagnosis. FDG-PET can be used as an adjunct test in solitary pulmonary nodule evaluation.[7] In assessing FDG-PET in staging patients with non-small cell carcinoma, FDG-PET had a higher sensitivity (71% vs 43%), positive predictive value (44% vs 31%), negative predictive value (91% vs 84%) & accuracy (76% vs 68%) than computed tomography (CT) scan for N2 lymph nodes. Whereas, FDG-PET had a higher sensitivity (67% vs. 41%) but lower specificity (78% vs. 88%) than CT scan for N1 lymph nodes. It accurately upstaged 28 patients (7%) with unsuspected metastasis & down-staged 23 patients (6%). Hence it can be concluded that the FDG-PET scan allows for improved patient selection & accurately stages the mediastinum. However, there were many false positives lymph nodes, and it may miss N2 disease in the #5, #6, and #7 stations.

A positive FDG-PET scan means a tissue biopsy is indicated in that location.[8] In FDG-PET evaluation of cancers of the esophagus and gastroesophageal junction, FDG-PET had lower accuracy in the diagnosis of locoregional nodes (N1–2) than combined CT (computed tomography) and EUS (endoscopic ultrasound) (48% vs. 69%) because of a lack of sensitivity (22% vs. 83%). The accuracy for distant nodal metastasis was significantly higher for FDG-PET than the combined use of CT & EUS. Sensitivity was no different, however, specificity was higher. FDG-PET correctly upstaged five patients (12%) from N1–2 stage to the M+Ly stage, while one was falsely downstaged by FDG-PET scanning.[9] In a study on the role of FDG PET scan in colorectal cancer screening in asymptomatic adults, it was found that sensitivity of FDG-PET to detect primary colorectal cancer is high, primary colorectal cancer being detected with FDG PET in a resectable stage. FDG-PET could detect large size (> 0.7 cm) and pre-malignant change of colonic adenomas. It’s possible to differentiate adenoma from carcinoma of the colon by assessing the increase in the rate of glycolysis in carcinoma.[10] 

FDG-PET has a role in the detection of recurrent cervical cancer in symptomatic and asymptomatic women. Thiry percent of asymptomatic women had recurrent disease detected by PET scan compared to 66.7% of symptomatic women. The sensitivity of PET for recurrent disease in asymptomatic women was 80.0%, specificity 100%, the positive predictive value of 100% and a negative predictive value of 88.9%. For symptomatic women, the sensitivity of PET was 100%, specificity 85.7%, the positive predictive value of 93.3%, and negative predictive value of 100%. Hence, whole-body PET can be a sensitive imaging modality for the detection of recurrent cervical carcinoma in both symptomatic and asymptomatic women also.[11] 

The 68-gallium DOTA peptide is used to detect primary and metastatic neuroendocrine tumors (NETs). NETs express somatostatin receptors (SSTRs), with SSTR2 (51%) of cases, followed by SSTR1 (47%) and SSTR5 (43%). The remaining SSTR4 (36%) and SSTR3 (23%) have low expression levels.[12][13] The 68-gallium DOTA PET-CT was able to detect significantly more lesions in patients with negative anatomical imaging compared with 111-ln-octreoscan (30 vs. 2; p = 0.028). Pfeifer et al. reported a sensitivity of 88% for ln-octreoscan in comparison to 97% for the 64-Cu DOTA PET-CT.[14] Srirajaskanthan et al. found 68-Gallium DOTA PET-CT scans to detect 74.3% of the lesions, whereas 111-ln-octreoscan detected 12% of the lesions.[15] The 68-Gallium DOTA PET-CT was found helpful in the detection of NETs in symptomatic patients with no evidence of disease on the basis of anatomical imaging and endoscopic evaluation, with or without biochemical evidence of disease. It significantly altered treatment in these patients who, on follow-up, had improvement in symptoms. Patients with a difficult diagnosis should be offered the 68-Gallium DOTA PET-CT.

Other tracers being used include C-labelled metomidate (11C-metomidate) for detecting adrenocortical tumors.[16][17] F-DOPA PET-CT ( F-DOPA PET-CT) is shown to be a sensitive alternative to find and localize pheochromocytoma than MIBG (meta-iodo benzyl guanidine) scan.[18][19]

Neurology

Areas of high radiotracer uptake are associated with higher brain activity. It measures indirectly the flow of blood through the brain, which has been correlated with areas of higher brain activity. Oxygen-15 is used for this.

Alzheimer disease results in decreased brain metabolism of both glucose and oxygen. [18F] FDG PET of the brain is used to differentiate Alzheimer disease from other dementias. Perfusion, glucose metabolism, and Aβ imaging have an established role and are included in the revised diagnostic criteria as important biomarkers. Florbetapir F18, flutemetamol F18, and florbetaben F18 are used to detect amyloid-beta plaques. Other targets include tau protein and neuro-inflammation. Protein kinase C (PKC) promotes the induction of alphasecretase or “a disintegrin and metalloprotease (ADAM)” non-amyloidogenic cleavage of amyloid precursor protein (APP) and hence have an important role in the acquisition and maintenance of memory in Alzheimer disease (AD). Deficits in PKC are seen early in the course of the disease. A selective PKC inhibitor, enzastaurin (LY317615), has recently been radiolabeled with C to be used as a potential probe for PET imaging applications.[20] P-Glycoprotein (P-gp) in the blood-brain barrier (BBB) has been thought to play a role in Aβ clearance from the brain. [11C] verapamil is a radiolabeled P-gp substrate used in PET studies, showing lower P-gp expression in subjects older than 75 years, but the increased expression in the young.[21] 

The cholinergic deficit has been studied with PET, the radio-labelled analog of acetylcholine, such as N-[(11) C]-methyl-4-piperidyl acetate (MP4A). Decreased cortical uptake is found in AD patients, with a greater reduction in Lewy body dementia more so in the posterior cingulate gyrus.[22] Radiolabeled cholinesterase inhibitors used for AD treatment like donepezil ([11C]donepezil) are used in assessing donepezil binding sites. A fluorinated tracer, 3-(benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro1H-indazole, [18F]-IND1, structurally related to the acetylcholinesterase inhibitor CP126,998, has been developed for the detection of acetylcholinesterase changes in AD patients.[23][24] PET scanning has resulted in improvement in the knowledge of the pathophysiology of atypical Parkinsonism disorders and may be used as supportive criteria for differential diagnosis of these conditions.[25] Brain PET imaging with FDG may be useful in seizure focus localization, which appears hypo-metabolic during an interictal scan. Various radiotracers for specific neuroreceptors have been developed like [11C] raclopride, [18F] fallypride and [18F] desmethoxyfallypride for dopamine D2/D3 receptors, [11C] McN 5652 and [11C] DASB for serotonin transporters, [18F] Mefway for serotonin 5HT1A receptors, [18F] nifene for nicotinic acetylcholine receptors or enzyme substrates (6-FDOPA for AADC enzyme). These help in the localization of these neuroreceptors in the pathogenesis of various neurologic diseases.

Neuropsychology: PET scanning helps delineate a link between specific processes and brain activity.

Psychiatry: Radiotracers binding to dopamine, serotonin, opioid, and cholinergic receptors are used to study their roles in various psychological disorders.

Stereotactic Surgery and Radiosurgery: PET-image guided surgeries are now being done.

Cariology

[18F]FDG-PET helps to identify hibernating myocardium. Imaging of atherosclerosis to detect patients at risk of stroke may also be done. Using FDG PET, we can detect inflammation quite early even before morphological and irreversible vascular changes are seen. Hence early diagnosis and treatment of large-vessel vasculitis are possible.[26]

Myocardial Perfusion Tracers: Tracers have been developed to visualize the myocardial blood flow, including nitrogen-13 (13N)-labeled ammonia and oxygen-15 –labeled water ([15O]-H2O) and rubidium-82 (82Rb)-chloride and copper-62 (62Cu)-labeled pyruvaldehyde bis (N4-methylthio-semicarbazone) or [62Cu]-PTSM. Only 13N and 82Rb are approved by the FDA.[27]

Myocardial Metabolic Tracers: The heart uses primarily free fatty acids (FFA) in oxidative metabolism. Ischemic & hypoxic myocardium prominently utilize glucose because of increased anaerobic glycolysis rate. Tracers to visualize this include  18F-FDG and carbon-11–labeled palmitate and acetate. PET with myocardial perfusion and [18F]-FDG quite accurately assesses myocardial viability & is considered the gold standard for assessing myocardial viability. Predicting functional recovery of heart, improvement in congestive heart failure symptoms, exercise capacity, quality of life, cardiac events, remodeling, and long-term survival is possible with PET.[27]

Infectious Diseases

PET can be used to image bacterial infections via 18F-FDG, by identifying infection-associated inflammatory response. Agents include [18F]maltose,[23] [18F]maltohexaose & [18F]2-fluorodeoxysorbitol (FDS).[28] FDS importantly targets only Enterobacteriaceae. Applications include FUO, vascular graft infections, musculoskeletal infections including osteomyelitis, joint prosthesis infections & diabetic foot infection. FDG-PET in osteomyelitis has improved spatial resolution over SPECT imaging, thereby allowing more accurate localization, which can be further improved by adding CT.[29] FDG-leukocyte imaging has been found comparable to In-oxine-leukocyte scintigraphy to detect infection. Applications of this technique include graft imaging, colonic inflammation & peritoneal tuberculosis.[30][31][32][33][34] 

Autoimmune Diseases

The upcoming role of PET is included in the new group of diseases called IgG4 diseases. FDG PET/CT isn’t included in standard sarcoidosis workup, but it’s efficient in the initial diagnosis and follows up of disease management. It can help to assess cardiac involvement, response to treatment, and evaluation of reversible granulomas as well as to determine the best site for biopsy.[35] 18F-FDG-PET can differentiate normal thyroid parenchyma from diffuse inflammatory changes of the thyroid gland in patients with autoimmune thyroid diseases (AITD).[36] FDG uptake in rheumatoid arthritis in affected joints reflects disease activity with the correlation between FDG and clinical parameters, monitoring the response to therapy also. FDG-PET/CT shows a high diagnostic value for polymyalgia rheumatica in differential diagnosis from rheumatoid arthritis.[37]

Musculoskeletal System Diseases

PET provides muscle activation data about deep-lying muscles compared with techniques like electromyography, which is useful in superficial muscles only. [18F]-NaF is used to measure regional bone metabolism and blood flow. [18F]NaF is recently being used in studying bone metastasis also.[38]